Remyelination, the process by which new myelin sheaths are restored to demyelinated axons, represents one of the most compelling examples of adult multipotent progenitor cells contributing to regeneration of the injured central nervous system (CNS). This process can occur with remarkable efficiency in both clinical disease, such as multiple sclerosis, and in experimental models, revealing an impressive ability of the adult CNS to repair itself. However, the inconsistency of remyelination in multiple sclerosis, and the loss of axonal integrity that results from its failure, makes enhancement of remyelination an important therapeutic objective. Identifying potential targets will depend on a detailed understanding of the cellular and molecular mechanisms of remyelination. In this article we address two important issues. First, we consider the nature of the cell or cells that respond to demyelination and generate new oligodendrocytes, identifying current areas of uncertainty and addressing the role of adult CNS stem and progenitor cells. Second, we discuss the concept of adult progenitor activation following demyelination, focusing on the increased expression of (1) olig transcription factors, (2) bone morphogenetic proteins and (3) fyn, a member of the src-family of tyrosine kinases.
Introduction
Following demyelination in the central nervous system (CNS), a hallmark event in the disease multiple sclerosis (MS), there are two possible outcomes (Fig. 1) . Either the axons remain demyelinated and are vulnerable to atrophy, an event that makes a significant contribution to the progressive phase of MS (De Stefano et al. 1998; Bjartmar et al. 2003) , or new myelin sheaths can be restored to the demyelinated axons in a spontaneous regenerative process called remyelination (Prineas et al. 1993; Lassmann et al. 1997) . It has been known for many years that remyelination restores saltatory conduction (Smith et al. 1979 ). More recently, however, it has become apparent that the presence of an intact myelin sheath has a profoundly beneficial effect on axonal integrity and that remyelination may therefore provide Correspondence Dr Robin Franklin, Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK. T: +44 (0)1223 337642; F: +44 (0)1223 337610; E: rjf1000@cam.ac.uk Accepted for publication 9 June 2005 Fig. 1 Demyelination occurs when the oligodendrocyte or the myelin sheath its produces and maintains is the target of the disease process. Once axons have been demyelinated there are two possible outcomes: either the axon remains demyelinated, in which case it is vulnerable to axonal or even neuronal loss, or the axon can be remyelinated. This process involves the generation of new oligodendrocytes that reinvest the demyelinated axons with the thin, short myelin internodes characteristic of remyelination. a highly effective means of preventing axonal loss in demyelinating disease (Griffiths et al. 1998; Kornek et al. 2000; Lappe-Siefke et al. 2003; Edgar et al. 2004; Xin et al. 2005) . Thus, while strategies to prevent demyelination remain a major focus of MS therapy, approaches that promote remyelination and minimize axonal loss represent an important adjunct to the therapeutic armoury. Developing such therapies is likely to depend on a detailed understanding of the mechanism of remyelination, from which will emerge a better understanding of why this repair process often fails in MS patients (Franklin, 2002; Franklin & Goldman, 2004) .
Several experimental models of CNS demyelination exist that have been used to study remyelination. Of these, the models that involve toxic death of oligodendrocytes have proved to be especially helpful because the demyelination is usually acute and focal and is followed by a defined and generally predictable regenerative response ( Fig. 2A,B) . From these models it has been possible to identify a sequence of events by which remyelination proceeds. The first event is the activation of a population of progenitor cells that then rapidly populate an area of demyelination by proliferating and migrating during the recruitment phase of remyelination. This phase then gives way to a second phase in which the recruited cells differentiate into oligodendrocytes, a highly specialized cell that generates new myelin sheaths around the demyelinated axons. This simple model of remyelination, which in its broad outline resembles many other regenerative processes in the body, raises a number of important questions. In this article we focus on two of these: what is the nature of the cell or cells that respond to demyelination and generate new oligodendrocytes, and how do these cells respond to injury in preparation for remyelination?
What cells give rise to remyelinating oligodendrocytes?
In most situations these cells are a distinctive phenotype widely referred to as adult oligodendrocyte progenitor cells (OPCs). These cells are the adult descendants of an extensively studied developmental progenitor, originally called the O-2A progenitor based on its ability in vitro to give rise to a distinctive type of astrocyte (the type 2 astrocyte) as well as oligodendrocytes (Raff et al. 1983; Wren et al. 1992) . Because the type 2 astrocyte is thought to occur infrequently, if at all, during normal development, these cells are now generally referred to as simply oligodendrocyte progenitor cells (Fulton et al. 1992; Levison & Goldman, 1993) . In adult tissue these cells have a characteristic multipolar morphology and express several markers, of which the proteoglycan NG2 and the growth factor receptor PDGFR α are the most commonly used (Nishiyama et al. 1996; Dawson et al. 2000 Dawson et al. , 2003 . Whether OPCs express both markers in all Fig. 2 (A) The EB-CCP lesion provides a useful model for studying the biology of CNS remyelination. A focal area of primary demyelination is created by stereotaxic injection of 4 µL of 0.01% EB into the large white matter tract of the caudal cerebellar peduncle (see Woodruff & Franklin, 1999) . (B) In young adult rats (2-4 months of age), the demyelination induced by EB injection undergoes a stereotypic process of remyelination in which there is first an OPC response which is then followed by the appearance of new oligodendrocytes (derived from the recruited OPCs) that remyelinate the demyelinated axons. The process is complete at around 28 days (see Sim et al. 2002a,b) . (C) Nkx2.2+ OPCs express high levels of BMP4 mRNA at 7 days after lesion induction. (D) Although there are many cell types within the lesion at this time point only a proportion are Nkx2.2+ OPCs, and the BMP4+ cells illustrated in C are all Nkx2.2+. Scale bar = 16 µm.
circumstances and in all regions of the adult CNS is uncertain (Hampton et al. 2004) ; indeed, the extent to which this is a homogeneous population of cells throughout the adult neuraxis is also unresolved. There is now clear evidence that oligodendrocytes can be generated via several distinct lineage pathways and therefore from a developmental perspective progenitor phenotypes are diverse (Mallon et al. 2002; Liu & Rao, 2004; Cai et al. 2005; Vallstedt et al. 2005) . For example, two distinct populations can be described on the basis of expression of PDGFR α or DM20, an alternatively spliced isoform of the proteolipid protein gene (Spassky et al. 1998 (Spassky et al. , 2000 . The component of the total remyelination attributable to SVZ-derived cells is uncertain but is likely to be small given the abundance and responsiveness of locally derived OPCs. A further uncertain issue is how close an area of demyelination must be in order for SVZ progenitors to respond. Although it is clear that lesions within the adjacent corpus callosum can induce this response, it is unlikely that white matter lesions remote from the SVZ in, for example, the spinal cord or brain stem white matter will do so given that most remyelinating cells are recruited from a narrow region surrounding a lesion (Franklin et al. 1997) . In white matter regions remote from the SVZ there is no clear evidence at present that cells other than OPCs contribute to remyelination.
Do CNS stem cells contribute to remyelination?
If one applies strict criteria to the definition of a stem cell When the same area of CNS is exposed to several rounds of demyelination/remyelination, the OPC numbers are not reduced and the efficiency of remyelination is not impaired by previous rounds of remyelination (Penderis et al. 2003) . This implies that a failure of remyelination is not due to an exhaustion of OPCs available to repopulate the demyelinated area and give rise to new oligodendrocytes. However, this appears only to be the case if sufficient time is left between demyelinating episodes to allow the OPC numbers to be replenished. 
Reactive OPCs -a critical phenotypic switch for remyelination?
The reactive changes that occur in astrocytes and microglia in response to CNS injury are well documented and comprise a series of phenotypic changes that distinguish the reactive state from the resting state. Similar reactive changes occur in OPCs (Levine et al. 2001 ). This was first described as a change in morphology and more intense staining with the OPC marker NG2 (Levine & Reynolds, 1999) . More recently it has become apparent that a number of distinct changes in gene expression occur that are associated with OPC activation. In this section we consider three of these, the Olig transcription factors, the bone morphogenetic proteins and the tyrosine kinase fyn.
Olig transcription factors
In the normal adult white matter PDGFR α + OPCs also express mRNA of the bHLH transcription factor Olig1 at levels easily detectable by in situ hybridization. By contrast, the mRNA expression levels of the related transcription factor Olig2 and the homeodomain transcription factor Nkx2.2 are below the threshold for detection by this method. However, the expression of both Olig2 and Nkx2.2 mRNA within OPCs dramatically increases following induction of focal demyelination (Fancy et al. 2004; Watanabe et al. 2004; Talbott et al. 2005) . The increase in Nkx2.2 expression occurs in the absence of detectable increases in sonic hedgehog mRNA expression (Fancy et al. 2004) , which is responsible for its induction during development but appears not to be required for CNS remyelination (Briscoe et al. 1999; Lu et al. 2000) . However, the increased expression of Olig2 mRNA could be accounted for by the rapid increase in expression of FGF-2 that occurs in toxin-induced demyelination (Hinks & Franklin, 1999) . During development, the convergence of expression of Olig2 and Nkx2.2 within the same cell population is a necessary event for these precursor cells to differentiate into oligodendrocytes (Sun et al. 2001; Zhou et al. 2001) . It seems possible therefore that the increased expression of these two genes in response to demyelination is a critical event required to convert quiescent OPCs into cells able to differentiate into remyelinating oligodendrocytes.
Consistent with this hypothesis, the increases in Olig2 and Nkx2.2 expression are delayed in old animals where the rate of OPC differentiation is slower than in young animals (Sim et al. 2002b; Fancy et al. 2004 ).
Bone morphogenetic proteins (BMPs)
BMPs, members of the transforming growth factor superfamily of growth factors, play important roles in the development of many cell types including CNS glial cells (Mehler et al. 1997) . They are also implicated in repair processes of several tissues, especially bone (Reddi, 1998) . Their effects on OPCs include (1) This model, called the EB-CCP, has been used in many studies to examine the biology of CNS remyelination (Sim et al. 2002a; Arnett et al. 2004; Stidworthy et al. 2004) (Fig. 2) . Using non-radioactive in situ hybridization, we found that neither BMP2 nor noggin were detectable in the demyelinated areas. Small numbers of weakly labelled BMP7 mRNA-expressing cells were seen at 14 days after lesion induction but not at earlier or later time points. However, many cells expressing readily detectable levels of BMP4 mRNA were detected within the lesion throughout the remyelination process. The distribution of BMP4-expressing cells resembled that of PDGFR α + OPCs, but with a lower density and staining intensity. By combining BMP4 in situ hybridization with immunocytochemistry using antibodies to Nkx2.2 (Fancy et al. 2004 ), we were able to confirm that the majority of BMP4+ cells were OPCs (Fig. 2C) . This co-labelling only occurred during the process of remyelination (Fig. 2B): when remyelination was complete at 28 days (Shields et al. 1999 To test this we used non-radioactive in situ hybridization with Fyn-specific cRNA probes. We initially confirmed the specificity of these probes by demonstrating Fyn mRNA expression during the myelination of white matter tracts in 2-3-day-old neonatal rats. In adult white matter, however, Fyn mRNA expression was barely at the level of detection. We then looked for Fyn mRNA-expressing cells after induction of demyelination in the adult rat using the EB-CCP model (Fig. 3) . Fyn mRNA-expressing cells were clearly detectable at 5 days after lesion induction and were most abundant after 7 days (Fig. 3A) .
Thereafter, the numbers gradually decreased. Double labelling studies revealed that a high proportion of Fyn mRNA-expressing cells also expressed Nkx2.2 (Fig. 3B) , and that Fyn therefore had increased levels of message expression occurring in reactive OPCs present within the lesion at early stages of remyelination before myelin sheaths appear (Shields et al. 1999; Woodruff & Franklin, 1999; Sim et al. 2000) . Fyn was exclusive to oligodendrocyte lineage cells because there was no colocalization with either astrocytes or macrophage/microglia. Although the prospects for devising pro-remyelination therapies are realistic and exciting there are many critical questions that need to be addressed. In this review we have raised several of these, including the diversity of progenitor cells types that can contribute to remyelination and the manner in which these cells become activated and are able to engage in the repair process. Resolving these questions will form a major part of the developing field of translational 'stem cell' regeneration therapies for demyelinating disease in the forthcoming years.
